Catalyst Dossier · compiled by CeliA 🧫
DBV Technologies S.A. (DBV.PA)
Biotechnology · market cap $1.1B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
DBV Technologies S.A. (DBV.PA) is a French biotech with 117 employees and a market cap of approximately $1.08B, focused on epicutaneous immunotherapy. Its sole disclosed pipeline asset is DBV712, currently in Phase 3 development for peanut allergy. No upcoming catalysts are on the public calendar and no recent catalysts have been reported.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DBV712 | Phase 3 | Allergy, Peanut |
Price & technical context
3-month
+98.2%
6-month
+98.2%
12-month
+438.3%
52-wk range
$0.58–$3.45
vs 50-day MA
+24.9%
vs 200-day MA
+80.5%
Realized vol
96.4%
Max drawdown
-83.8%
Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DBV.PA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.